EUVIMEDEUVIMED entdecken
Open Access

Plasma Kidney Injury Molecule-1 for Preoperative Prediction of Renal Cell Carcinoma Versus Benign Renal Masses, and Association With Clinical Outcomes

Wenxin Xu iD, Valerie Gaborieau, Samuel M Niman, Anush Mukeria iD, Xiaowen Liu, Krishna P Maremanda iD, Ayumi Takakura, David Zaridze iD, Matthew L Freedman iD, Wanling Xie iD, David F McDermott iD, Toni K Choueiri iD und 7 weitere

Journal of Clinical Oncology · 01.08.2024 · 42 (22) · 2691-2701

DOI: 10.1200/jco.23.00699 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.08.2024. Verfasst von Wenxin Xu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Hepatitis A Virus Cellular Receptor 1. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Congressionally Directed Medical Research Programs, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Both clear cell and papillary renal cell carcinomas (RCCs) overexpress kidney injury molecule-1 (KIM-1). We investigated whether plasma KIM-1 (pKIM-1) may be a useful risk stratification tool among patients with suspicious renal masses. METHODS Prenephrectomy pKIM-1 was measured in two independent cohorts of patients with renal masses. Cohort 1, from the prospective K2 trial, included 162 patients found to have clear cell RCC (cases) and 162 patients with benign renal masses (controls). Cohort 2 included 247 patients with small (cT1a) renal masses from an academic biorepository, of whom 184 had RCC. We assessed the relationship between pKIM-1, surgical pathology, and clinical outcomes. RESULTS In Cohort 1, pKIM-1 distinguished RCC versus benign masses with area under the receiver operating curve (AUC-ROC, 0.81 [95% CI, 0.76 to 0.86]). In Cohort 2 (cT1a only), pKIM-1 distinguished RCC versus benign masses (AUC-ROC, 0.74 [95% CI, 0.67 to 0.80]) and the addition of pKIM-1 to an established nomogram for predicting malignancy improved the model AUC-ROC (0.65 [95% CI, 0.57 to 0.74] v 0.78 [95% CI, 0.72 to 0.85]). A pKIM-1 cutpoint identified using Cohort 2 demonstrated sensitivity of 92.5% and specificity of 60% for identifying RCC in Cohort 1. In long-term follow-up of RCC cases (Cohort 1), higher prenephrectomy pKIM-1 was associated with worse metastasis-free survival (multivariable MFS hazard ratio [HR] 1.29 per unit increase in log pKIM-1, 95% CI, 1.10 to 1.53) and overall survival (multivariable OS HR 1.31 per unit increase in log pKIM-1, 95% CI, 1.10 to 1.54). In long-term follow-up of Cohort 2, no metastatic events occurred, consistent with the favorable prognosis of resected cT1a RCC. CONCLUSION Among patients with renal masses, pKIM-1 is associated with malignant pathology, worse MFS, and risk of death. pKIM-1 may be useful for selecting patients with renal masses for intervention versus surveillance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHepatitis A Virus Cellular Receptor 1HumansMaleFemaleMiddle AgedAgedBiomarkers, TumorProspective StudiesROC CurveNephrectomyAdultPrognosisPredictive Value of Tests

Substanzen

Hepatitis A Virus Cellular Receptor 1HAVCR1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Dana-Farber Cancer Institute, Boston, MA.
  • International Agency for Research on Cancer, Lyon, France.
  • N.N. Blokhin National Medical Research Centre of Oncology, Moscow, Russia.
  • Beth Israel Deaconess Medical Center, Boston, MA.
  • Brigham and Women's Hospital, Boston, MA.
  • Penn Presbyterian Medical Center, Philadelphia, PA.

ORCID-Profile: Wenxin Xu, Anush Mukeria, Krishna P Maremanda, David Zaridze, Matthew L Freedman, Wanling Xie, David F McDermott, Toni K Choueiri, Paul J Catalano, Phillip M Pierorazio, Nirmish Singla, Paul Brennan

Förderung

  • NCI NIH HHS
  • Congressionally Directed Medical Research Programs
  • NIDDK NIH HHS
  • Dana-Farber/Harvard Cancer Center Kidney SPORE
  • NIH HHS
  • NCATS NIH HHS
  • World Health Organization

Zitieren

APA

Xu, W., Gaborieau, V., Niman, S. M., Mukeria, A., Liu, X., Maremanda, K. P., Takakura, A., Zaridze, D., Freedman, M. L., Xie, W., McDermott, D. F., Choueiri, T. K., Catalano, P. J., Sabbisetti, V., Bonventre, J. V., Pierorazio, P. M., Singla, N., Brennan, P., & Bhatt, R. S. (2024). Plasma Kidney Injury Molecule-1 for Preoperative Prediction of Renal Cell Carcinoma Versus Benign Renal Masses, and Association With Clinical Outcomes. Journal of Clinical Oncology, 42(22), 2691-2701. https://doi.org/10.1200/jco.23.00699

Vancouver

Xu W, Gaborieau V, Niman SM, Mukeria A, Liu X, Maremanda KP, et al. Plasma Kidney Injury Molecule-1 for Preoperative Prediction of Renal Cell Carcinoma Versus Benign Renal Masses, and Association With Clinical Outcomes. Journal of Clinical Oncology. 2024;42(22):2691-2701. doi:10.1200/jco.23.00699

BibTeX
@article{Xu2024,
  author = {Xu, Wenxin and Gaborieau, Valerie and Niman, Samuel M and Mukeria, Anush and Liu, Xiaowen and Maremanda, Krishna P and Takakura, Ayumi and Zaridze, David and Freedman, Matthew L and Xie, Wanling and McDermott, David F and Choueiri, Toni K and Catalano, Paul J and Sabbisetti, Venkata and Bonventre, Joseph V and Pierorazio, Phillip M and Singla, Nirmish and Brennan, Paul and Bhatt, Rupal S},
  title = {Plasma Kidney Injury Molecule-1 for Preoperative Prediction of Renal Cell Carcinoma Versus Benign Renal Masses, and Association With Clinical Outcomes},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {22},
  pages = {2691--2701},
  doi = {10.1200/jco.23.00699}
}
Kostenlos starten →